Eton Pharmaceuticals (ETON)

[BioSpecialist]

Deals which just closed in last 6 months :

Bausch Health acquires U.S. rights for Eton's eye drop ..2019-02-19
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aBHC-2719331


"EM-100. EM-100, Eton’s preservative-free ophthalmic solution for allergic conjunctivitis has been assigned a target action date of July 11, 2019.

EM-100 Ophthalmic Solution

•Innovative over-the-counter ophthalmic solution for treatment of allergic conjunctivitis

•If approved, EM-100 would be the first preservative-free ophthalmic product indicated for allergic conjunctivitis

•Product has been filed with the FDA and is expected to be approved in 2019

•U.S. allergic conjunctivitis ophthalmic market is >$600 million annually

•Eton partnered with Bausch Health for commercialization

•Eton receives additional milestone payment upon approval and a royalty on net sales


Eton Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application and Provides Pipeline Update
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-licensing-lamotrigine-new-drug

Unique patent-pending formulation of lamotrigine addresses significant unmet need in pediatric epilepsy patients

NDA was submitted in May 2019; product launch anticipated in 1H 2020

Lamotrigine market currently exceeds $700 million annually



Eton Pharmaceuticals Enters Into License Agreement for Two Branded Hospital Product Candidates
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-enters-license-agreement-two-branded



Eton Pharmaceuticals Announces Licensing of Oral Liquid Product Candidate ET-104
https://ir.etonpharma.com/news-releases/news-release-details/eton-pharmaceuticals-announces-licensing-oral-liquid-product